The COVID-19 treatment guidelines (2019-electronic format) published by the National Institute for Health (NIH) are to be updated by the COVID-19 Treatment Guidelines Panel to ensure HCPs, patients, and policymakers have the most recent information for the optimal management of COVID-19. The major revisions to the guidelines were made in August for the following areas: Anti-SARS-CoV-2 monoclonal antibodies New information is updated regarding the invitro susceptibility of circulating SARS-CoV-2 variants of concern to the available anti-SARS-CoV-2 monoclonal antibodies (mAbs).
Anticipated clinical activity of various anti-SARS-Cov-2 mAbs against the newly dominant subvariants Omicron BA.4 and BA.5 Considerations for immunocompromised patients A new section is added to the guidelines for high-risk immunocompromised individuals for whom COVID may cause progression of the existing condition…
